Yosef E Maruvka
Overview
Explore the profile of Yosef E Maruvka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
5358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Negm L, Chung J, Nobre L, Bennett J, Fernandez N, Nunes N, et al.
Lancet Oncol
. 2024 Dec;
26(1):123-135.
PMID: 39701117
Background: Gliomas are a major cause of cancer-related death among children, adolescents, and young adults (age 0-40 years). Primary mismatch repair deficiency (MMRD) is a pan-cancer mechanism with unique biology...
2.
Hezi H, Gelber M, Balabanov A, Maruvka Y, Freiman M
Comput Methods Programs Biomed
. 2024 Nov;
259:108513.
PMID: 39581068
Background And Objective: Treatment approaches for colorectal cancer (CRC) are highly dependent on the molecular subtype, as immunotherapy has shown efficacy in cases with microsatellite instability (MSI) but is ineffective...
3.
Hezi H, Shats D, Gurevich D, Maruvka Y, Freiman M
PLoS One
. 2024 Sep;
19(9):e0309380.
PMID: 39255280
Molecular subtypes of colorectal cancer (CRC) significantly influence treatment decisions. While convolutional neural networks (CNNs) have recently been introduced for automated CRC subtype identification using H&E stained histopathological images, the...
4.
Ercan A, Aronson M, Fernandez N, Chang Y, Levine A, Liu Z, et al.
Lancet Oncol
. 2024 Mar;
25(5):668-682.
PMID: 38552658
Background: Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes,...
5.
Das A, Fernandez N, Levine A, Bianchi V, Stengs L, Chung J, et al.
Cancer Discov
. 2023 Oct;
14(2):258-273.
PMID: 37823831
Significance: Hypermutant RRD-HGG are susceptible to checkpoint inhibitors beyond initial progression, leading to improved survival when reirradiation and synergistic immune/targeted agents are added. This is driven by their unique biological...
6.
Geffen Y, Anand S, Akiyama Y, Yaron T, Song Y, Johnson J, et al.
Cell
. 2023 Aug;
186(18):3945-3967.e26.
PMID: 37582358
Post-translational modifications (PTMs) play key roles in regulating cell signaling and physiology in both normal and cancer cells. Advances in mass spectrometry enable high-throughput, accurate, and sensitive measurement of PTM...
7.
Isozaki H, Sakhtemani R, Abbasi A, Nikpour N, Stanzione M, Oh S, et al.
Nature
. 2023 Jul;
620(7973):393-401.
PMID: 37407818
Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical problem. Although many drivers of acquired drug resistance have been identified, the underlying molecular mechanisms shaping tumour evolution during...
8.
Das A, Tabori U, Sambira Nahum L, Collins N, Deyell R, Dvir R, et al.
Clin Cancer Res
. 2023 May;
29(23):4770-4783.
PMID: 37126021
Purpose: Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring...
9.
Rheinbay E, Nielsen M, Abascal F, Wala J, Shapira O, Tiao G, et al.
Nature
. 2023 Jan;
614(7948):E40.
PMID: 36697832
No abstract available.
10.
Waldman S, Backenroth D, Harney E, Flohr S, Neff N, Buckley G, et al.
Cell
. 2022 Dec;
185(25):4703-4716.e16.
PMID: 36455558
We report genome-wide data from 33 Ashkenazi Jews (AJ), dated to the 14 century, obtained following a salvage excavation at the medieval Jewish cemetery of Erfurt, Germany. The Erfurt individuals...